REQUEST A DEMO
Total
USD $0.00
Search more companies

Novavax Cz A.S. (Czech Republic)

Main Activities: Pharmaceutical and Medicine Manufacturing | Other Miscellaneous Nondurable Goods Merchant Wholesalers
Secondary Activities: All Other Miscellaneous Chemical Product and Preparation Manufacturing | Surgical and Medical Instrument Manufacturing | Other Miscellaneous Store Retailers | Research and Development in Nanotechnology | Materials Recovery Facilities
Full name: Novavax Cz A.S. Profile Updated: December 05, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Novavax CZ a.s. operates as a research and development and manufacturing-related entity within Novavax, a global biotechnology company focused on vaccines. The Czech operations are associated with development support, testing, manufacturing and quality activities related to recombinant protein-based vaccines and adjuvant technologies. Operations are integrated into Novavax's global R&D and production network. Geographic scope is international through group-level programs. Key assets include biotechnology expertise, regulated laboratory and production environments and integration into global vaccine development pipelines. Strategic focus emphasizes innovation in vaccine technologies, quality assurance and support of global public health initiatives.

Headquarters
Libalova 2348/1
Prague; The City of Prague; Postal Code: 14900

Contact Details: Purchase the Novavax Cz A.S. report to view the information.

Website: https://www.novavax.com/

Basic Information
Total Employees:
Purchase the Novavax Cz A.S. report to view the information.
Registered Capital:
Purchase the Novavax Cz A.S. report to view the information.
Financial Auditors:
Purchase the Novavax Cz A.S. report to view the information.
Incorporation Date:
April 07, 2017
Key Executives
Purchase this report to view the information.
Proxy
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Novavax Cz A.S. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CZK. Absolute financial data is included in the purchased report.
Net sales revenue
-55.76%
Total operating revenue
87.39%
Operating profit (EBIT)
38.59%
EBITDA
-5.03%
Net Profit (Loss) for the Period
-10.23%
Total Assets
-40.86%
Total Equity
12.5%
Operating Profit Margin (ROS)
33.98%
Net Profit Margin
8.15%
Return on Equity (ROE)
-2.82%
Quick Ratio
-0.09%
Cash Ratio
0.25%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?